Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › H2020

GALAXY · GALAXY: Gut-and-liver axis in alcoholic liver fibrosis

H2020Status: CLOSED1 January 201631 December 2021EU funding €6,305,654Call H2020-PHC-2014-2015

Alcohol overuse is an important societal challenge with annual healthcare costs of over €22 billion in Europe. Alcohol is the main cause of liver cirrhosis, which is the 5th and 7th most common cause of life years lost in respectively Eastern and Western Europe. Cirrhosis is considered irreversible but its precursor, liver fibrosis, is reversible when detected before disease progression. GALAXY proposes that crosstalk between the gut microbiome and the liver influences the development and progression of alcoholic liver fibrosis. Here, a ‘dysbiotic’ microbiome in susceptible individuals leads to progressive liver fibrosis in combination with alcohol overuse. Therefore, interventions aiming to restore a healthy gut microbiome will reduce disease development. We will use state-of-the-art systems medicine tools to improve understanding of the complex interplay present during alcoholic liver fibrosis, to identify at-risk individuals in time and to develop personalised healthcare strategies for alcohol over-users (20% of the EU population >15 years old). GALAXY brings together partners with unique research competences in clinical hepatology, microbiome, multi-omics, biomarkers and bioinformatics. Our aim is to develop novel systems medicine tools which integrate clinical, multi-omics and lifestyle information from alcohol over-users at various stages of the disease and healthy individuals in order to: 1) identify signatures of host-microbial cross-talk during disease development and progression, 2) translate this into biomarkers for diagnosis, stratification and treatment monitoring in alcohol over users, and 3) evaluate new interventions to modulate gut microbiota towards prevention and mitigation of the disease in at-risk individuals. We will also study societal and economic impact of GALAXY biomarkers and treatments to accelerate future development. The GALAXY consortium includes strong SME partners who will enable the results to be exploited commercially.

Consortium · 13 organisations

coordinator

SYDDANSK UNIVERSITET

DK · €639,843

participant

NOVO NORDISK INVEST 4 A/S

DK · €130,279

participant

REGION HOVEDSTADEN

DK · €328,686

participant

NORGINE BV

NL

participant

REGION SYDDANMARK

DK · €1,187,082

participant

EUROPEAN MOLECULAR BIOLOGY LABORATORY

DE · €1,387,000

participant

UNIVERSITATSKLINIKUM BONN

DE · €353,241

participant

KOBENHAVNS UNIVERSITET

DK · €928,752

participant

IDRYMA IATROVIOLOGIKON EREUNON AKADEMIAS ATHINON

EL · €427,987

participant

JOHANN WOLFGANG GOETHE-UNIVERSITAET FRANKFURT AM MAIN

DE · €247,369

participant

UNIVERSITETET I OSLO

NO · €195,127

participant

NORDISK REBALANCE AS

DK · €178,907

participant

NORDIC BIOSCIENCE A/S

DK · €301,381

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.